Phase II Study of Pembrolizumab and Itacitinib for Patients with Metastatic NSCLC Expressing PD-L1: Long-Term Follow up

被引：0
|
作者：
Marmarelis, M. E. [1 ]
Cantor, D. J. [1 ]
Mathew, D. [1 ]
McWilliams, T. [1 ]
Bauml, J. [2 ]
Hwang, W-T [1 ]
Singh, A. [1 ]
D'Avella, C. [1 ]
Davis, C. [1 ]
Ye, D. [1 ]
Sun, L. [1 ]
Ciunci, C. [1 ]
Aggarwal, C. [1 ]
Cohen, R. B. [1 ]
Minn, A. [1 ]
Wherry, J. [1 ]
Langer, C. J. [1 ]
机构：
[1] Univ Penn, Philadelphia, PA USA
[2] Janssen, Philadelphia, PA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Immunotherapy; JAK; Pembrolizumab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA06.04
引用
收藏
页码：S20 / S20
页数：1
相关论文
共 50 条
  • [21] Association of PD-L1/CD8+TIL and expression of PD-L1, PTEN as predictive biomarkers for long-term follow-up in early breast cancer.
    Toh, Uhi
    Okabe, Mina
    Iwakuma, Nobutaka
    Saku, Shuko
    Akashi, Momoko
    Ogo, Etsuyo
    Itoh, Kyogo
    Akagi, Yoshito
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Prognostic value of the Scottish Inflammatory prognostic Score in patients with NSCLC expressing PD-L1 ≥ 50 % progressing on first-line pembrolizumab
    Stares, Mark
    Doyle, Emma
    Chapple, Sally
    Raynes, George
    MacDonald, James
    Barrie, Colin
    Laird, Barry
    MacKean, Melanie
    Philips, Iain
    LUNG CANCER, 2024, 189
  • [23] Predictive factors of efficacy to pembrolizumab in advanced NSCLC patients with high PD-L1 expression.
    Piedra, A.
    Barba Joaquin, A.
    Mosquera Martinez, J.
    Fernandez Bruno, M.
    Cordeiro Gonzalez, P.
    Sullivan, I. G.
    Riudavets Melia, M.
    Aguado Sorolla, M.
    Gallardo Melo, P.
    Martin Cullell, B.
    Gavira, J.
    Tapia, J. C.
    Romano, A.
    Bosma, F.
    Sanchez Del Rio, S.
    Sanz Beltran, J.
    Molina Perez, M. A.
    Serra Lopez, J.
    Garcia Campelo, M. R.
    Majem Tarruella, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1053 - S1053
  • [24] Phase 3 Trofuse-007 Study: Sacituzumab Tirumotecan Plus Pembrolizumab vs Pembrolizumab Alone for NSCLC with PD-L1 TPS ≥50%
    Frost, N.
    Ghori, R.
    Roy, A.
    Nunes, A. T.
    Yang, J. C. -H.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S389 - S390
  • [25] Evaluation of PD-L1 and Ki67 markers in CTCs of NSCLC patients treated with pembrolizumab
    Spiliotaki, M.
    Charalambous, H.
    Neophytou, C. M.
    Gregoriou, G.
    Vogazianos, P.
    Deltas, C.
    Constantinou, A. I.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S709 - S709
  • [26] 5-Year Survival of Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With PD-L1 Tumor Proportion Score <1%
    Gadgeel, S.
    Rodriguez-Abreu, D.
    Halmos, B.
    Garassino, M. C.
    Kurata, T.
    Cheng, Y.
    Jensen, E.
    Shamoun, M.
    Rajagopalan, K.
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S77 - S78
  • [27] Macrophages are important source of PD-L1 and PD-L1 expressing on central M2 macrophages leads to the poor prognosis of NSCLC patients: Via macrophage landscape analysis for NSCLC patients with tumor PD-L1 negative
    Cao, Lili
    Che, Xiaofang
    Qu, Xiujuan
    Qiu, Xueshan
    Li, Zhi
    Yang, Bowen
    Wang, Shuo
    Liu, Yunpeng
    CANCER RESEARCH, 2019, 79 (13)
  • [28] Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598
    Boyer, M.
    Sendur, M. A. N.
    Rodriguez-Abreu, D.
    Park, K.
    Lee, D. H.
    Cicin, I.
    Yumuk, P. F.
    Orlandi, F.
    Leal, T.
    Molinier, O.
    Soparattanapaisam, N.
    Langleben, A.
    Califano, R.
    Medgyasszay, B.
    Hsia, T.
    Otterson, G.
    Xu, L.
    Piperdi, B.
    Samkari, A.
    Reck, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S61 - S62
  • [29] Efficacy of Pembrolizumab vs. Nivolumab Plus Ipilimumab in Metastatic NSCLC in Relation to PD-L1 and TMB Status
    Shalata, Walid
    Maimon Rabinovich, Natalie
    Agbarya, Abed
    Yakobson, Alexander
    Dudnik, Yulia
    Abu Jama, Ashraf
    Cohen, Ahron Yehonatan
    Shalata, Sondos
    Abu Hamed, Ahmad
    Ilan Ber, Tahel
    Machluf, Oshri
    Shoham Levin, Gal
    Meirovitz, Amichay
    CANCERS, 2024, 16 (10)
  • [30] Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up
    Chalmers, Anna W.
    Patel, Shiven
    Boucher, Ken
    Cannon, Laura
    Esplin, Michelle
    Luckart, Julie
    Graves, Natalie
    Van Duren, Terry
    Akerley, Wallace
    TARGETED ONCOLOGY, 2019, 14 (04) : 417 - 421
12345